Carmona F, Font J, Cervera R, Muñoz F, Cararach V, Balasch J
Institut de Ginecologia, Obstetricia i Neonatologia, Hospital Clínic i Provincial-Institut dInvestigacions Biomèdiques August Pi i Sunyer, Faculty of Medicine, University of Barcelona, Spain.
Eur J Obstet Gynecol Reprod Biol. 1999 Apr;83(2):137-42. doi: 10.1016/s0301-2115(98)00312-1.
To analyze the course of maternal diseases and the outcome of pregnancy in patients with systemic Lupus Erythematosus (SLE).
During a period of 11 years we prospectively followed 60 pregnancies in 46 SLE patients in a tertiary care center in Barcelona (Spain). The management protocol included: (1) planning of conception when disease was inactive; (2) frequent follow-up visits by an internist-obstetrician team; (3) use of sequential ultrasonographic, Doppler and fetal echocardiographic examinations; (4) serial evaluations of maternal immunological condition; and (5) low dose aspirin from 1 month before attempting conception and throughout pregnancy was added in women with antiphospholipid antibodies. From 1985 until 1994 prednisone prophylaxis was used in all lupus patients during the last month of pregnancy and during the first month of the puerperium; from 1995 onwards this regime was abandoned.
The mean (S.D.) age of patients was 28.6 (4.8) years (range 20 to 42) and the mean (S.D.) previous duration of SLE was 6.25 (4.8) years (range 0 to 17). SLE was diagnosed during the pregnancy in two cases (3.3%) and the disease was active at conception in four cases (6.7%); at that time nine patients (15%) were taking prednisone. Antiphospholipid antibodies were positive in 16 patients (30.4%) and there were 10 (16.7%) pregnancies in patients having lupus nephropathy. There were three first-trimester miscarriages (5%) and four (6.7%) voluntary abortions. Obstetric complications in the remaining 53 pregnancies included: preterm delivery, 11 cases (20.8%); intrauterine growth retardation, five cases (9.4%); hypertension, 10 patients (18.9%), five of them fulfilling the criteria of preeclampsia; premature rupture of membranes, four patients (7.5%); finally, 13 neonates had a birthweight lower than 2500 g. There were 15 lupus flares (28.3%), giving a flare rate of 0.044 per patient/month. There were five neonatal deaths (perinatal mortality rate, 94 per thousand): one because of complete heart block, three due to severe hyaline membrane disease resulting from extreme prematurity and one intrauterine death in a patient having the Leiden mutation.
Pregnancy in patients with SLE should not be regarded as an unacceptable high-risk condition for the mother or her baby provided that conception is accurately planned and patients are managed according to a careful multidisciplinary treatment schedule.
分析系统性红斑狼疮(SLE)患者的母体疾病病程及妊娠结局。
在11年期间,我们前瞻性地追踪了西班牙巴塞罗那一家三级医疗中心46例SLE患者的60次妊娠情况。管理方案包括:(1)疾病不活动时计划受孕;(2)由内科医生 - 产科医生团队进行频繁的随访;(3)使用连续超声、多普勒和胎儿超声心动图检查;(4)对母体免疫状况进行系列评估;(5)对有抗磷脂抗体的女性,从尝试受孕前1个月至整个孕期添加低剂量阿司匹林。1985年至1994年,所有狼疮患者在妊娠最后1个月和产褥期第1个月使用泼尼松预防;从1995年起放弃该方案。
患者的平均(标准差)年龄为28.6(4.8)岁(范围20至42岁),SLE既往平均(标准差)病程为6.25(4.8)年(范围0至17年)。2例(3.3%)在孕期诊断出SLE,4例(6.7%)在受孕时疾病活动;当时9例患者(15%)正在服用泼尼松。16例患者(30.4%)抗磷脂抗体呈阳性,10例(16.7%)患有狼疮性肾病的患者妊娠。有3例孕早期流产(5%)和4例(6.7%)人工流产。其余53次妊娠的产科并发症包括:早产11例(20.8%);胎儿生长受限5例(9.4%);高血压10例(18.9%),其中5例符合先兆子痫标准;胎膜早破4例(7.5%);最后,13例新生儿出生体重低于2500g。有15次狼疮病情活动(28.3%),患者每月的病情活动率为0.044。有5例新生儿死亡(围产儿死亡率为千分之94):1例因完全性心脏传导阻滞,3例因极早产导致的严重透明膜病,1例在患有莱顿突变的患者中发生宫内死亡。
只要准确计划受孕并根据精心制定的多学科治疗方案对患者进行管理,SLE患者的妊娠不应被视为对母亲或其婴儿不可接受的高风险情况。